AC Immune Doses First Patient in Final ABATE Trial Cohort, Triggers $12M Takeda Milestone

AC Immune SA (NASDAQ: ACIU) announced the initiation of the final cohort (AD4) in its ongoing Phase 1b/2 ABATE trial evaluating ACI-24, an anti-Abeta active immunotherapy for Alzheimer’s disease. The dosing of the first patient in this cohort triggered a $12 million milestone payment from Takeda under their existing worldwide option and license agreement. The ABATE trial is designed to assess the safety, tolerability, and immunogenicity of ACI-24 in patients with prodromal Alzheimer’s and adults with Down syndrome. Cohort AD4 will initially include 36 patients, significantly expanding the safety and biomarker data set, with the potential to expand to approximately 112 subjects. Current data indicates ACI-24 is generally safe and well-tolerated, showing anti-Abeta antibody responses across all doses. Under the Takeda agreement, AC Immune is eligible for up to $2.1 billion in total milestones plus tiered double-digit royalties. The company expects to report 12-month data readouts from the previous cohorts (AD1, AD2, and AD3) later in Q2 2026.